KDventures AB 

€0.013200
0
+€0.00+3.13% Thursday 06:10

Statistics

Day High
0.0132
Day Low
0.0132
52W High
0.0941
52W Low
0.0078
Volume
0
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2I9.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BridgeBio Pharma
BBIO
Mkt Cap13.08B
BridgeBio Pharma focuses on genetic diseases and targeted therapies, similar to Karolinska Development's investment in biotech and pharmaceutical companies.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, paralleling Karolinska's focus on high-impact medical conditions.
Sarepta Therapeutics
SRPT
Mkt Cap1.62B
Sarepta Therapeutics specializes in precision genetic medicine, competing in the same innovative biotechnology space as Karolinska Development.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, similar to Karolinska's strategy in life sciences investments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap37.76B
Alnylam Pharmaceuticals works on RNAi therapeutics, a cutting-edge approach in biotech where Karolinska Development also invests.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is a leader in gene editing technology, a field relevant to Karolinska Development's interest in groundbreaking medical technologies.
Novo Nordisk
NVO
Mkt Cap194.35B
Novo Nordisk is a global healthcare company with a focus on innovative treatments for diabetes and other serious chronic conditions, aligning with Karolinska's investment focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals is known for its scientific capabilities in biopharmaceuticals, directly competing with Karolinska's portfolio companies.
Bio-Techne
TECH
Mkt Cap8.45B
Bio-Techne develops, manufactures, and sells biotechnology products and clinical diagnostic controls, overlapping with Karolinska's biotech interests.

About

Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.
Show more...
CEO
ISIN
SE0002190926

Listings

0 Comments

Share your thoughts

FAQ

What is KDventures AB stock price today?
The current price of 2I9.MU is €0.01 EUR — it has increased by +3.13% in the past 24 hours. Watch KDventures AB stock price performance more closely on the chart.
What is KDventures AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange KDventures AB stocks are traded under the ticker 2I9.MU.
Is KDventures AB stock price growing?
2I9.MU stock has risen by +0% compared to the previous week, the month change is a +6.45% rise, over the last year KDventures AB has showed a -84.4% decrease.
In which sector is KDventures AB located?
KDventures AB operates in the Other sector.
When did KDventures AB complete a stock split?
KDventures AB has not had any recent stock splits.